Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China

Table 1 Characteristics of patients receiving curative and palliative surgery n (%)

Variable	Curative surgery (n = 381)	Palliative surgery (n = 330)
Age (median [range])	60 [26-82]	58 [19-80]
Sex, male (%)	231 (60.6)	178 (53.9)
Presenting symptoms
Jaundice	267 (70.1)	240 (72.7)
Weight loss	26 (6.8)	22 (6.7)
Abdominal pain	24 (6.3)	28 (8.5)
Nausea and vomiting	20 (5.2)	17 (5.1)
General fatigue	44 (11.6)	23 (7.0)
Tumor markers (median [range])
Preoperative CA 19-9 level, U/mL	348 [0.6-1000]	539.9 [0.6-3015.2]
Preoperative CA 125 level, U/mL	19.84 [1.23-257.70]	33.94 [1.54-1598.00]
Preoperative CEA level, ng/mL	3.23 [0.20-65.51]	4.44 [0.47-1000.00]
Liver functions (median [range])
Preoperative TB level, umol/L	209.4 [7.1-586.3]	239.65 [1.90-805.70]
Preoperative ALT level, U/L	95 [10-967]	78.5 [6.0-1212.0]
Preoperative AST level, U/L	86 [14-1016]	87 [11-927]
Preoperative Albumin level, g/L	36.7 [18.7-51.8]	35.95 [21.30-72.50]
Preoperative hospital stay (median [range])	7 [2-44]	7 [3-48]
Total hospital stay (median [range])	19 [9-113]	16 [4-102]
Portal vein embolization	53 (13.9)
Biliary drainage	201 (52.8)
Estimated blood loss (median [range])	600 [50-2000]	348 [0.6-1000]
Bismuth-Corlette classification
Type I	95 (25.2)	16 (4.8)
Type II	92 (24.2)	59 (17.9)
Type IIIa or IIIb	102 (26.8)	102 (30.9)
Type IV	92 (24.2)	153 (46.4)

ALT: Alanine aminotransferase; AST: Aspartate transaminase; CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; TB: Total bilirubin.